Results 141 to 150 of about 190,042 (189)
Some of the next articles are maybe not open access.
Expert Opinion on Pharmacotherapy, 2000
Since its discovery, nearly 90 years, heparin has been used successfully for the treatment of thromboembolic processes. However, therapy with heparin has several important limitations. Most importantly, the poor predictability of its anticoagulant effects has led to the development of the low molecular weight heparins (LMWHs), which are derived from ...
O M, Aguilar, N S, Kleiman
openaire +3 more sources
Since its discovery, nearly 90 years, heparin has been used successfully for the treatment of thromboembolic processes. However, therapy with heparin has several important limitations. Most importantly, the poor predictability of its anticoagulant effects has led to the development of the low molecular weight heparins (LMWHs), which are derived from ...
O M, Aguilar, N S, Kleiman
openaire +3 more sources
Current Opinion in Cardiology, 1994
Low molecular weight heparins are derived from unfractionated heparin by chemical or enzymatic depolymerization; as a result, the mean molecular weight of unfractionated heparin is reduced by about one third and its biochemical and pharmacologic properties are improved.
B, Cosmi, J, Hirsh
openaire +2 more sources
Low molecular weight heparins are derived from unfractionated heparin by chemical or enzymatic depolymerization; as a result, the mean molecular weight of unfractionated heparin is reduced by about one third and its biochemical and pharmacologic properties are improved.
B, Cosmi, J, Hirsh
openaire +2 more sources
Heparin and low-molecular-weight heparin
Thrombosis and Haemostasis, 2008SummaryHeparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration.
Elaine, Gray +2 more
openaire +2 more sources
Journal of Vascular Nursing, 1997
Traditionally unfractionated heparin is given in the hospital and then followed with 3 to 6 months of oral anticoagulant therapy. Hospitalization is expensive, intravenous administration of heparin limits mobility, and the patient is exposed to iatrogenic infections.
openaire +2 more sources
Traditionally unfractionated heparin is given in the hospital and then followed with 3 to 6 months of oral anticoagulant therapy. Hospitalization is expensive, intravenous administration of heparin limits mobility, and the patient is exposed to iatrogenic infections.
openaire +2 more sources
Medical Clinics of North America, 1994
Low molecular weight heparins (LMWHs) are mixtures of heparin molecules in the range of 3000 to 10,000 daltons. As LMWHs of various manufacturers are all produced differently, they are not comparable to each other and are therefore considered to be individual products with different pharmacologic and clinical properties.
openaire +2 more sources
Low molecular weight heparins (LMWHs) are mixtures of heparin molecules in the range of 3000 to 10,000 daltons. As LMWHs of various manufacturers are all produced differently, they are not comparable to each other and are therefore considered to be individual products with different pharmacologic and clinical properties.
openaire +2 more sources
The Journal of Urology, 1997
After almost two decades of intensive research, low-molecular-weight heparins have established their niche as an important class of antithrombotic compounds. The demonstration that these compounds are safe and effective for the prevention and treatment of venous thromboembolism has led to the licensing of several of them in Europe and North America. In
openaire +2 more sources
After almost two decades of intensive research, low-molecular-weight heparins have established their niche as an important class of antithrombotic compounds. The demonstration that these compounds are safe and effective for the prevention and treatment of venous thromboembolism has led to the licensing of several of them in Europe and North America. In
openaire +2 more sources
Heparins, Low-Molecular-Weight Heparins, and Pentasaccharides
Clinics in Geriatric Medicine, 2006Elderly patients require special consideration when administered anticoagulants because of age-related alterations in renal function, protein binding, and increased bleeding risk. Unfractionated heparin can be used in most patients but difficulties with dosing and monitoring often lead to inadequate anticoagulation.
Danya L, Dinwoodey, Jack E, Ansell
openaire +2 more sources
Drugs & Aging, 1992
The introduction of low molecular weight heparins has added a new dimension to the management of thrombotic disorders. Ten LMWHs are currently available for clinical use. Although these agents have been primarily developed and used in European countries, other countries, including the US, have started to evaluate their usefulness.
D, Hoppensteadt, J M, Walenga, J, Fareed
openaire +2 more sources
The introduction of low molecular weight heparins has added a new dimension to the management of thrombotic disorders. Ten LMWHs are currently available for clinical use. Although these agents have been primarily developed and used in European countries, other countries, including the US, have started to evaluate their usefulness.
D, Hoppensteadt, J M, Walenga, J, Fareed
openaire +2 more sources
Low molecular weight heparin, heparin, and warfarin
Current Opinion in Hematology, 1995Low molecular weight heparin is effective for the prevention and treatment of venous thromboembolism. Low molecular weight heparin has the practical advantage that it does not require anticoagulant monitoring and dose adjustment. The simplified therapy provided by low molecular weight heparin may allow many patients with venous thromboembolism to be ...
openaire +2 more sources